Medpace Holdings, Inc. (MEDP) Earnings
Medpace Holdings, Inc. is expected to report next earnings on July 20, 2026 (in NaN days), with a consensus EPS estimate of $3.98. MEDP has beaten EPS estimates in 12 of its last 12 reported quarters (average surprise +9.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 23, 2026 | $3.74 | $4.28 | +14.4% | $707M | +1.3% |
| Oct 22, 2025 | $3.53 | $3.86 | +9.3% | $660M | +2.9% |
| Jul 21, 2025 | $2.98 | $3.10 | +4.0% | $603M | +12.0% |
| Jul 22, 2024 | $2.54 | $2.75 | +8.3% | $528M | -0.1% |
| Jul 24, 2023 | $1.91 | $1.93 | +1.0% | $461M | +2.8% |
| Feb 13, 2023 | $1.79 | $2.12 | +18.4% | $394M | +2.1% |
| Jul 25, 2022 | $1.31 | $1.46 | +11.5% | $351M | +2.1% |
| Feb 14, 2022 | $1.25 | $1.32 | +5.6% | $309M | -0.2% |
| Feb 15, 2021 | $1.24 | $1.35 | +8.9% | $260M | +9.7% |
| Jul 27, 2020 | $0.41 | $0.68 | +65.9% | $205M | +56.1% |
| Apr 28, 2020 | $0.75 | $0.80 | +6.7% | $231M | +1.3% |
| Feb 24, 2020 | $0.75 | $0.85 | +13.3% | $230M | +13.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 23, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Key managerial messages include acknowledging Jesse Geiger's 18.5 years of service, discussing Q1 results with cancellations, net bookings, RFPs, strong initial reward notifications and win rate, EBITDA and net income figures, customer concentration, cash flow from operating activity, and net day sales outstanding.
Guidance
2026 guidance ranges for revenue, EBITDA, net income, and EPS are unchanged from the prior quarter based on an effective tax rate of 19 to 20% and interest income of $27.5 million. There are no additional share purchases in the guidance.
Segment performance
Revenue for the first quarter of 2026 was $706.6 million, representing a year-over-year increase of 26.5%. EBITDA was $149.4 million, up 25.9% compared to the prior year. Net income was $123.9 million, up 8.1% compared to the prior year period. Ending backlog as of March 31st, 2026 was approximately $2.9 billion, an increase of 2.9% from the prior year, with approximately $1.94 billion of backlog projected to convert to revenue in the next 12 months.
Risks & headwinds
Discussions on cancellations being a factor, impact of M&A on ongoing work, variability in RFP trends, AI investment needing significant outlay before net benefit, and potential risks from backlog conversion issues.